Search

Your search keyword '"Negrier, Sylvie"' showing total 304 results

Search Constraints

Start Over You searched for: Author "Negrier, Sylvie" Remove constraint Author: "Negrier, Sylvie"
304 results on '"Negrier, Sylvie"'

Search Results

51. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†

54. Prognosis impact of serous metastases (SMs) in clear cell renal cell carcinoma patients in the GETUG-AFU-26 NIVOREN phase II trial.

55. Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).

56. A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).

57. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

63. Safety and efficacy of nivolumab in older patients (pts) with renal cell carcinoma: Results of a sub-group analysis of the GETUG-AFU 26 NIVOREN multicenter phase II study.

64. Association of statins and nivolumab activity in patients with metastatic renal cell carcinoma (mRCC): Results from the phase II nivoren—GETUG AFU 26 trial.

66. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study

67. A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).

68. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial

69. Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab + axitinib (A+Ax) versus sunitinib (S).

70. NIVOREN GETUG-AFU 26 translational study: Association of PD-1, AXL, and PBRM-1 with outcomes in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N).

71. Validation of the lung immune prognostic index (LIPI) in patients with metastatic renal cell carcinoma treated with nivolumab in the GETUG-AFU 26 NIVOREN trial.

72. Utility of a general molecular screening program in patients with GU malignancies: The ProfiLER trial experience.

73. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

74. Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma

77. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

79. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma

82. Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

85. CPT-11/L-OHP/5-FU/LV COMBINATION BEFORE LIVER SURGERY IN PATIENTS WITH NOT OPTIMALLY RESECTABLE COLORECTAL CANCER LIVER METASTASES: METHODOLOGY AND PRELIMINARY RESULTS, PHASE II STUDY: 646

86. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma- less efficacy compared with intravenous interleukin-2 and interferon alpha

87. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma

89. ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy.

90. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

91. Are immune checkpoint inhibitors (ICI) a valid option for papillary renal cell carcinoma (pRCC)? A multicenter retrospective study.

95. Interpreting overall survival results when progression-free survival benefits exist in today’s oncology landscape: a metastatic renal cell carcinoma case study

98. Optimizing axitinib treatment selection following first-line sunitinib in metastatic renal cell carcinoma.

100. CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas

Catalog

Books, media, physical & digital resources